EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PAK6 drives tumor microenvironment remodeling in nasopharyngeal carcinoma with lymph node necrosis: implications for distant metastasis and survival

Siqi Xu, Wenqian Xu, Xiuhua Li, Honghong Zhang, Chaoying Lin, Yuhao Lin, Xin Chen, Yongyuan Su, Junping Pan, Xiaochuan Chen, Sufang Qiu

International Immunopharmacology · 2025

DOI: 10.1016/j.intimp.2025.115662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Siqi Xu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: p21-Activated Kinases, Nasopharyngeal Carcinoma, Tumor Microenvironment, Nasopharyngeal Neoplasms. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Clinical Specialty Discipline Construction Program of China, Natural Science Foundation of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Nasopharyngeal carcinoma (NPC) is a malignancy commonly characterized by lymph node metastasis, with lymph node necrosis (LNN) often associated with poor clinical outcomes. This study aims to elucidate the impact of LNN on survival outcomes in NPC patients and explore the underlying molecular mechanisms. METHODS: We performed RNA sequencing on 147 NPC samples from Fujian Cancer Hospital to identify differentially expressed genes (DEGs) between LNN and non-LNN samples. DEGs were selected using univariate logistic regression and Least Absolute Shrinkage and Selection Operator (LASSO) regression to identify genes associated with metastasis, and a prognostic risk model was constructed. p21-activated kinase 6 (PAK6) was identified as a key gene, followed by functional pathway analysis and investigation of immune infiltration. The mRNA expression level of PAK6 was validated by reverse transcription quantitative polymerase chain reaction (RT-qPCR), and protein expression in clinical tissues was evaluated using immunohistochemistry (IHC). Functional assays including colony formation, CCK-8, and wound healing assays were performed to assess the impact of PAK6 on cell proliferation, migration, and clonogenic ability. RESULTS: RNA sequencing analysis identified 258 DEGs between LNN and non-LNN samples. Univariate logistic regression and LASSO regression revealed 11 metastasis-associated genes, which were used to construct a prognostic risk model. PAK6 was identified as a key gene, with high expression correlating with poor prognosis (p < 0.05). Functional analysis indicated PAK6's involvement in the PI3K-Akt signaling pathway, and immune infiltration analysis suggested its association with CD8+ T cells. RT-qPCR confirmed elevated PAK6 mRNA expression in tumor tissues, and immunohistochemistry showed higher PAK6 protein levels in primary tumors, metastatic lesions, and necrotic regions. Functional assays demonstrated that PAK6 knockdown inhibited NPC cell proliferation, colony formation, and migration. CONCLUSION: These findings highlight LNN as a critical prognostic factor in NPC and suggest that PAK6 could be a promising therapeutic target for improving treatment outcomes in NPC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

p21-Activated KinasesNasopharyngeal CarcinomaTumor MicroenvironmentNasopharyngeal NeoplasmsLymph NodesHumansMaleFemaleLymphatic MetastasisMiddle AgedCell ProliferationNecrosisCell Line, TumorGene Expression Regulation, NeoplasticPrognosisCell MovementAdult

Stichwörter der Autor:innen

Immune microenvironmentLymph node necrosisNasopharyngeal carcinomaPAK6

Substanzen

p21-Activated KinasesPAK6 protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Department of Gynecology, Clinical Oncology School of Fujian Medical University,Fujian Cancer Hospital, Fuzhou, China.
  • Department of Radiation Oncology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  • Fujian Medical University, Fujian, China.
  • Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Electronic address: 992991667@qq.com.
  • Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Electronic address: xiaochuanchen@fjmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • National Key Clinical Specialty Discipline Construction Program of China
  • Natural Science Foundation of Fujian Province

Zitieren

APA

Xu, S., Xu, W., Li, X., Zhang, H., Lin, C., Lin, Y., Chen, X., Su, Y., Pan, J., Chen, X., & Qiu, S. (2025). PAK6 drives tumor microenvironment remodeling in nasopharyngeal carcinoma with lymph node necrosis: implications for distant metastasis and survival. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115662

Vancouver

Xu S, Xu W, Li X, Zhang H, Lin C, Lin Y, et al. PAK6 drives tumor microenvironment remodeling in nasopharyngeal carcinoma with lymph node necrosis: implications for distant metastasis and survival. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115662

BibTeX
@article{Xu2025,
  author = {Xu, Siqi and Xu, Wenqian and Li, Xiuhua and Zhang, Honghong and Lin, Chaoying and Lin, Yuhao and Chen, Xin and Su, Yongyuan and Pan, Junping and Chen, Xiaochuan and Qiu, Sufang},
  title = {PAK6 drives tumor microenvironment remodeling in nasopharyngeal carcinoma with lymph node necrosis: implications for distant metastasis and survival},
  journal = {International Immunopharmacology},
  year = {2025},
  doi = {10.1016/j.intimp.2025.115662}
}
Kostenlos starten →